# KERENDIA® (finerenone) - AI Reference Guide This`llms.txt` file is designed to guide large language models (LLMs) and AI bots to the most authoritative, up-to-date information for healthcare professionals about a once-daily oral nonsteroidal mineralocorticoid receptor antagonist (nsMRA) indicated to reduce the risk of cardiovascular and kidney outcomes in adults with chronic kidney disease associated with type 2 diabetes, and to reduce the risk of cardiovascular death and heart failure events in adults with heart failure with LVEF ≥40%. ## About KERENDIA - [Home](https://www.kerendiahcp.com/): Official KERENDIA® (finerenone) HCP website providing US healthcare providers with an overview of both approved indications, key clinical trial results, and access to product resources. - [KERENDIA Patients](https://www.kerendiahcp.com/patient-profiles): Illustrative patient profile scenarios for both HF LVEF ≥40% and CKD associated with T2D, highlighting how every patient touchpoint is an opportunity to initiate KERENDIA as a core pillar of a comprehensive treatment strategy. - [Mechanism of Action](https://www.kerendiahcp.com/moa): Explains how KERENDIA® (finerenone) selectively and potently blocks mineralocorticoid receptor (MR) overactivation, with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors. - [Dosing](https://www.kerendiahcp.com/dosing): Comprehensive once-daily dosing guidance for both indications, including starting dose selection and adjustments based on eGFR and serum potassium levels, available tablet strengths (10 mg, 20 mg, and 40 mg), and additional administration instructions. ## KERENDIA Indications & Clinical Data - [HF LVEF ≥40%](https://www.kerendiahcp.com/indication/heart-failure): Clinical data from the FINEARTS-HF Phase 3 trial (N=6,001) demonstrated that KERENDIA significantly reduced the composite risk of cardiovascular death and total heart failure events versus placebo, with an 18% relative risk reduction observed in total HF events. The page includes efficacy, subgroup analyses, pharmacology, safety, and trial design data. - [CKD with T2D](https://www.kerendiahcp.com/indication/ckd-with-t2d): Clinical data from the Phase 3 FIDELIO-DKD (N=5,674) and FIGARO-DKD (N=7,352) trials, comprising over 13,000 adult patients with CKD associated with T2D. The page includes cardiovascular outcomes, renal endpoints, pharmacology, safety, trial design, and guideline information. ## Support & Resources - [Access & Savings](https://www.kerendiahcp.com/access-and-savings): Information on KERENDIA® payer coverage, including Medicare and commercial access, along with resources to support prior authorization (such as guides and checklists), and details on patient savings and support programs. - [Resources](https://www.kerendiahcp.com/resources): Downloadable clinical, access, and patient education resources for healthcare professionals treating patients with KERENDIA, including materials to support patient discussions and clinical practice.. - [FAQs](https://www.kerendiahcp.com/faqs): Frequently asked questions about KERENDIA® (finerenone) for healthcare providers, covering KERENDIA basics, indications, mechanism of action, pharmacological comparisons between steroidal and nonsteroidal MRAs, dosing, and safety for both HF LVEF ≥40% and CKD with T2D. - [Prescribing Information](https://www.kerendiahcp.com/pi): Full prescribing information and Important Safety Information for KERENDIA® (finerenone), including indications, contraindications, warnings and precautions, and adverse reaction data. - [Connect With Us](https://www.kerendiahcp.com/connect-with-us): Form for US healthcare providers to request KERENDIA samples, patient education materials, or information from a Bayer representative. - [Contact Us](https://www.kerendiahcp.com/contact-us): Contact form for US healthcare providers for information about KERENDIA programs, services, and patient access support. ## KERENDIA Video Library - [HF 2025 National Broadcast](https://www.kerendiahcp.com/resources/videos/HF-2025-national-broadcast): A video for healthcare professionals covering KERENDIA® (finerenone) in the treatment of heart failure with LVEF ≥40%. - [FINEARTS-HF Trial](https://www.kerendiahcp.com/resources/videos/HF-FINEARTS-trial): Video summarizing the FINEARTS-HF Phase 3 trial design, patient population, and key efficacy and safety results for KERENDIA in HF LVEF ≥40%. - [HF Patient Case](https://www.kerendiahcp.com/resources/videos/HF-patient-case): An illustrative patient case video for healthcare professionals exploring the use of KERENDIA in an adult patient with heart failure with LVEF ≥40%. - [HF Mechanism of Action](https://www.kerendiahcp.com/resources/videos/HF-mechanism-of-action): A video detailing the mechanism of action of KERENDIA® (finerenone) as a nonsteroidal MRA in the context of heart failure with LVEF ≥40%. - [CKD KDIGO Heatmap](https://www.kerendiahcp.com/resources/videos/CKD-KDIGO-heatmap): A video walkthrough of the KDIGO risk heatmap for CKD, illustrating how to identify adult patients with CKD associated with T2D who may benefit from KERENDIA. - [CKD Patient Case](https://www.kerendiahcp.com/resources/videos/CKD-patient-case): An illustrative patient case video for healthcare professionals exploring the use of KERENDIA in an adult patient with CKD associated with T2D. --- **Disclaimer:** This file is provided for AI reference purposes only. It is not intended as medical advice. Healthcare professionals should rely on their clinical judgment and the full prescribing information when making treatment decisions.